Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;39(2):301-310.
doi: 10.1093/fampra/cmab096.

Pharmacotherapy interventions for adolescent co-occurring substance use and mental health disorders: a systematic review

Kelli Scott  1   2 , Sara J Becker  1   2 , Sarah A Helseth  1 , Ian J Saldanha  3   4 , Ethan M Balk  3 , Gaelen P Adam  3 , Kristin J Konnyu  3 , Dale W Steele  3   5
Affiliations

Pharmacotherapy interventions for adolescent co-occurring substance use and mental health disorders: a systematic review

Kelli Scott et al. Fam Pract. .

Abstract

Background: Co-occurring mental health and substance use (SU) disorders among adolescents are common, with two-thirds of adolescents who seek SU treatment also requiring support for mental health. Primary care physicians play a key role in the pharmacological treatment of mental health disorders among adolescents, however, little is known about the impact of these treatments on SU outcomes.

Objectives: This systematic review summarizes the evidence regarding commonly used pharmacotherapy interventions for mental health and their impact on adolescent SU.

Methods: Literature searches were conducted across five databases as part of a larger systematic review of adolescent SU interventions. Studies were screened for eligibility by two researchers, and study data were extracted regarding study design, patient and treatment characteristics and results. Risk of bias analyses and qualitative syntheses were completed to evaluate the strength of the evidence and the impact of pharmacotherapy on SU outcomes.

Results: Ten randomized controlled trials exploring seven pharmacotherapies met criteria for inclusion. All studies had low to moderate risk of bias. Four studies evaluated pharmacotherapy for co-occurring depression and SU, three evaluated attention deficit hyperactivity disorder and SU, and three evaluated bipolar disorder and SU. Five of the 10 studies also included a behavioural intervention. We found no evidence that pharmacotherapy for co-occurring mental health diagnoses impacted SU.

Conclusion: Family medicine clinicians prescribing pharmacotherapy for mental health should be aware that additional interventions will likely be needed to address co-occurring SU.

Keywords: adolescent medicine; co-occurring disorders; mental health; pharmacotherapy; substance use; systematic review.

Plain language summary

Many adolescents have both mental health and substance use problems. Adolescents have difficulty getting effective treatment for both substance use and mental health concerns, in part because these treatments are often offered separately. Primary care physicians, who often care for adolescents with mental health concerns, may prescribe medications for diagnoses such as attention deficit hyperactivity disorder, depression or early symptoms of bipolar disorder. However, there is little research indicating whether these medications are helpful for co-occurring substance use disorder symptoms. This paper presents a review of existing research on medications used to treat common mental health disorders to evaluate their effect on substance use. Ten studies address this question and suggest that medications for mental health are insufficient for helping adolescents with substance use disorders or substance use problems.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flowchart of included studies.
Figure 2.
Figure 2.
Percentage of studies of pharmacotherapy for co-occurring SU and mental health disorders (N = 10) that meet criteria for each risk of bias category. Adapted from Steele et al. (27). Reprinted from original AHRQ report.
See this image and copyright information in PMC

References

    1. Brewer S, Godley MD, Hulvershorn LA. Treating mental health and substance use disorders in adolescents: what is on the menu? Curr Psychiatry Rep 2017; 19(1): 5. - PubMed
    1. Chan YF, Dennis ML, Funk RR. Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. J Subst Abuse Treat 2008; 34(1): 14–24. - PMC - PubMed
    1. O’Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev 2011; 31(1): 104–12. - PubMed
    1. Zaso MJ, Park A, Antshel KM. Treatments for adolescents with comorbid ADHD and substance use disorder: a systematic review. J Atten Disord 2020; 24(9): 1215–26. - PMC - PubMed
    1. Shane PA, Jasiukaitis P, Green RS. Treatment outcomes among adolescents with substance abuse problems: the relationship between comorbidities and post-treatment substance involvement. Eval Program Plann 2003; 26(4): 393–402.

Publication types